%PDF-1.4
%
36 0 obj
<>
endobj
33 0 obj
<>
endobj
105 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-07-29T18:27:33Z
2024-03-28T22:08:15-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T22:08:15-07:00
application/pdf
Heather
2002-1044.sept
uuid:705c6725-1dd2-11b2-0a00-e50827bd3700
uuid:705c6728-1dd2-11b2-0a00-5b0000000000
endstream
endobj
22 0 obj
<>
endobj
23 0 obj
<>
endobj
37 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 12 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 14 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 16 0 R/Type/Page>>
endobj
115 0 obj
[120 0 R]
endobj
116 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 0 k
/GS1 gs
420 777 137 -27 re
f*
0 0 0 1 K
54 54 m
558 54 l
S
BT
0 0 0 1 k
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2003; 30:9)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(1962)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.1 396.47 -10.84 re
f*
0.5 w
109.25 59.1 396.47 -10.84 re
S
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.0663 Tw 10 0 0 10 54 713.1616 Tm
(having been serologically quiescent developing these labo-)Tj
0.1991 Tw 0 -1.2 TD
(ratory features, and about 20% of the patients becoming)Tj
0 Tw T*
(SACQ.)Tj
0.05009 Tw 1.2 -1.2 Td
[(W)80 (e were unable to identify factors that could be used to)]TJ
0.29829 Tw -1.2 -1.2 Td
(separate concordant from discordant patients before the)Tj
0.1998 Tw T*
(eventual course of each individual patient was observed.)Tj
0.1476 Tw T*
(This suggests that serological monitoring of SLE patients)Tj
0.0172 Tc 0.3577 Tw T*
(would be useful only if followed longitudinally and)Tj
-0.00011 Tc 0.2003 Tw T*
[(frequently)65 (, first to identify the concordance status of the)]TJ
0.0322 Tw T*
(patient, and then to incorporate this information into subse-)Tj
0.1801 Tw T*
[(quent clinical decisions. )18 (This also suggests that in future)]TJ
0.0244 Tw T*
(longitudinal studies of this issue, discordant patients should)Tj
0.1889 Tw T*
(be identified and separated out from analyses of concor-)Tj
0 Tw T*
(dance.)Tj
/T1_2 1 Tf
0 -2.4 TD
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 61 523.1616 Tm
[(1.)-875 (Kof)18 (fler D, Schur PH, Kunkel HG. Immunological studies)]TJ
1.675 -1.25 Td
(concerning the nephritis of systemic lupus erythematosus. J Exp)Tj
0 Tc 0 -1.25 TD
(Med 1967;126:607-25.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(2.)-875 (Schur PH, Sandson J. Immunologic factors and clinical activity in)]TJ
1.675 -1.25 Td
(lupus erythematosus. N Engl J Med 1968;278:533-8.)Tj
-1.675 -1.25 Td
[(3.)-875 (Lightfoot R)55 (W)-257 (Jr)55 (., Hughes GR)80 (V)129 (. Significance of persisting serologic)]TJ
1.675 -1.25 Td
[(abnormalities in SLE. )55 (Arthritis Rheum 1976;19:837-43.)]TJ
-1.675 -1.25 Td
[(4.)-875 (Morrow )18 (WJW)92 (, Isenber)18 (g DA, )18 (T)70 (odd-Popropek )55 (A, Parry HF)80 (, Snaith)]TJ
1.675 -1.25 Td
(ML. Useful laboratory measurements in the management of)Tj
T*
(systemic lupus erythematosus. Q J Med 1982;51:125-38.)Tj
-1.675 -1.25 Td
[(5.)-875 (Isenber)18 (g DA, Shoenfeld )37 (Y)129 (, Schwartz RS. Multiple serologic )]TJ
1.675 -1.25 Td
(reactions and their relationship to clinical activity in systemic lupus)Tj
T*
[(erythematosus. )55 (Arthritis Rheum 1984;27:132-8.)]TJ
-1.675 -1.25 Td
[(6.)-875 (Esdaile JM, )55 (Abrahamowicz M, Joseph L, MacKenzie )18 (T)74 (, Li )37 (Y)129 (,)]TJ
1.675 -1.25 Td
[(Danof)18 (f D. Laboratory tests as predictors of disease exacerbations in)]TJ
T*
[(systemic lupus erythematosus: why some tests fail. )55 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1996;39:370-8.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(7.)-875 (T)70 (er Bor)18 (g EJ, Horst G, Hummel EJ, Limbur)18 (g PC, Kallenber)18 (g CGM.)]TJ
1.675 -1.25 Td
[(Measurement of increases in anti-double-stranded DNA)-220 (antibody)]TJ
T*
(levels as a predictor of disease exacerbation in systemic lupus)Tj
T*
[(erythematosus: a long-term, prospective study)65 (. )55 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1990;33:624-43.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(8.)-875 (Bootsma H, Spronk P)111 (, Derksen R, et al. Prevention of relapses in)]TJ
1.675 -1.25 Td
(systemic lupus erythematosus. Lancet 1995;345:1595-9.)Tj
-1.675 -1.25 Td
[(9.)-875 (Zonana-Nachach )55 (A, Salas M, S\207nchez L, Camar)18 (go-Coronel )55 (A,)]TJ
1.675 -1.25 Td
(Bravo-Gatica C, Mintz G. Measurement of clinical activity of)Tj
T*
(systemic lupus erythematosus and laboratory abnormalities: a )Tj
T*
[(12-month prospective study)65 (. J Rheumatol 1995;22:45-9.)]TJ
-2.175 -1.25 Td
[(10.)-875 (Adler MK, Baumgarten )55 (A, Hecht B, Siegel NJ. Prognostic )]TJ
2.175 -1.25 Td
(significance of DNA-binding capacity patterns in patients with)Tj
0 Tc T*
[(lupus nephritis. )55 (Ann Rheum Dis 1975;34:444-50. )]TJ
-0.00011 Tc 30.8619 61.421 Td
[(1)37 (1.)-875 (Ravirajan CT)74 (, Rowse L, MacGowan JR, Isenber)18 (g DA. )55 (An analysis)]TJ
2.1381 -1.25 Td
(of clinical disease activity and nephritis-associated serum )Tj
T*
(autoantibody profiles in patients with systemic lupus )Tj
T*
[(erythematosus: a cross-sectional study)65 (. Rheumatology)65 (, Oxford)]TJ
0 Tc 0 Tw T*
(2001;40:1405-12.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(12.)-875 (Appel )55 (AE, Sablay LB, Golden RA, Barland P)111 (, Grayzel )55 (AI, Bank N.)]TJ
2.175 -1.25 Td
[(The ef)18 (fect of normalization of serum complement and anti-DNA)]TJ
T*
(antibody on the course of lupus nephritis: a two year prospective)Tj
0 Tc T*
[(study)65 (. )55 (Am J Med 1978;64:274-83.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(13.)-875 (Laitman RS, Glicklich D, Sablay LB, Grayzel )55 (AI, Barland P)111 (, Bank)]TJ
2.175 -1.25 Td
[(N. Ef)18 (fect of long-term normalization of serum complement levels)]TJ
T*
[(on the course of lupus nephritis. )55 (Am J Med 1989;87:132-8.)]TJ
-2.175 -1.25 Td
[(14.)-875 (Gladman DD, Urowitz MB, Keystone EC. Serologically active )]TJ
2.175 -1.25 Td
(clinically quiescent systemic lupus erythematosus: a discordance)Tj
T*
[(between clinical and serologic features. )55 (Am J Med 1979;66:210-5.)]TJ
-2.175 -1.25 Td
[(15.)-875 (W)80 (alz Le Blanc BA, Gladman DD, Urowitz MB. Serologically)]TJ
2.175 -1.25 Td
(active clinically quiescent systemic lupus erythematosus\321)Tj
T*
(predictors of clinical flares. J Rheumatol 1994;21:2239-41.)Tj
-2.175 -1.25 Td
[(16.)-875 (W)80 (alz Le Blanc BA, Urowitz MB, Gladman DD. Serologically)]TJ
2.175 -1.25 Td
(active, clinically quiescent systemic lupus erythematosus\321)Tj
T*
(longterm followup. J Rheumatol 1994;21:174-5.)Tj
-2.175 -1.25 Td
[(17.)-875 (Lee P)111 (, Urowitz MB, Bookman )55 (AAM, et al. SLE: )55 (A)-220 (review of 1)37 (10)]TJ
2.175 -1.25 Td
(cases with particular reference to lupus nephritis, CNS )Tj
T*
(manifestations, infections, aseptic necrosis and prognosis. Q J Med)Tj
0 Tc 0 Tw T*
(1977;46:1-32.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(18.)-875 (Gladman DD, Ibanez D, Urowitz MB. SLEDAI 2000. J Rheumatol)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(2002;29:288-91. )Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(19.)-875 (Ibanez D, Urowitz MB, Gladman DD. Disease activity over )]TJ
2.175 -1.25 Td
(time \320 the adjusted mean and variability measure. J Rheumatol)Tj
0 Tc 0 Tw T*
(2001;28:1419. )Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(20.)-875 (Kallenber)18 (g CG, Bootsma H, Spronk PE, ter Bor)18 (g EJ, Derksen RH,)]TJ
2.175 -1.25 Td
(Kater L. Laboratory tests as predictors of flares in systemic lupus)Tj
T*
[(erythematosus [comment]. )55 (Arthritis Rheum 1997;40:393-4)]TJ
-2.175 -1.25 Td
[(21.)-875 (Bootsma H, Spronk PE, )18 (T)70 (er Bor)18 (g EJ, et al. )18 (The predictive value of)]TJ
2.175 -1.25 Td
[(fluctuations in IgM and IgG class anti-dsDNA)-220 (antibodies for)]TJ
T*
[(relapses in systemic lupus erythematosus. )55 (A)-220 (prospective long-term)]TJ
0 Tc T*
[(observation. )55 (Ann Rheum Dis 1997;56:661-6.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(22.)-875 (Buyon JP)111 (, )18 (T)70 (amerius J, Belmont HM, )55 (Abramson SB. )55 (Assessment of)]TJ
2.175 -1.25 Td
(disease activity and impending flare in patients with systemic lupus)Tj
T*
(erythematosus. Comparison of the use of complement split products)Tj
T*
[(and conventional measurements of complement. )55 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1992;35:1028-37.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(23.)-875 (Mollnes )18 (TE, Haga HJ, Brun JG, et al. Complement activation in)]TJ
2.175 -1.25 Td
(patients with systemic lupus erythematosus without nephritis.)Tj
0 Tc T*
(Rheumatology 1999;38:933-40.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(24.)-875 (Nagy G, Brozik M, )18 (T)70 (ornoci L, Ger)18 (gely P)111 (. Diagnostic value of)]TJ
2.175 -1.25 Td
[(combined evaluation of neopterin and anti-DNA)-220 (antibody levels for)]TJ
T*
(assessment of disease activity in systemic lupus erythematosus.)Tj
T*
(Clin Exp Rheumatol 2000;18:699-705.)Tj
-2.175 -1.25 Td
[(25.)-875 (Urowitz MB. SLE subsets\321 divide and conquer)55 (. J Rheumatol)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(1977;4:332-3.)Tj
ET
0 0 0 0 k
408 770 150 -25 re
f*
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
ET
/GS2 gs
BT
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
16 0 obj
<>stream
8;Z\6$#[[H#ikq,j?(mM"#e'P8QD`!&Nr'bS2Ekj,CXs(sNul[W9E
cH1e:kAK9PCL;D`ORhX[Vn"ki`.'g*/ib/[V7ag31VBYA9FWTg*\BS$ghJDG/,+p7\]/LlOB-YPnJBIB?g-MR
E[8`^C00?Op1_[m5qlUq`dH\p6Y@\LXSBB!HI2m*A!A-P!FFBViEoQ"Y43XbF1^Y(
D@W4oBtfkbjO]W@KU39=4*W?ReY,Dn0tOCPSR]!#8muEP%BHJ49b%G*pQ'>Q4X%NS
X?9h9'TfU@GADd1L=miSGYBsrTR*WIA)_o&`.K9>h/Vkd#@Xp;50S-"]/m-1)d2cB
?;F+B-bu`<+F_DK>'1+#X-`a&?=h((L)>4Y)0tq`!uG-Ob2Mi>+o&6KVaJBWe7G8a]b('F="d43GB!49A=ii^$[b0Y^Rp"\IhiHBpHbrfr!J)C1,>A
X@OV$D`Y4AAO07p"AJ)t-]R2+"UK"R[cO+#fJQFLG"`3W!YI1q`)[#]4[lBj`$%R^
7F"HqR-q]^g2!n*p<+f[p5"oha/>rl47+]bU-G.!T=1p(!#WmZH2~>
endstream
endobj
20 0 obj
[/Indexed/DeviceRGB 255 19 0 R]
endobj
19 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
45 0 obj
<>
endobj
48 0 obj
<>
endobj
61 0 obj
<>
endobj
89 0 obj
<>
endobj
110 0 obj
<>
endobj
58 0 obj
<>
endobj
71 0 obj
<>stream
HLPgw /\ure,GuCJE(9^$nZ
I XTUX="PK^-ӛڞֱwgiϮof]<μ}DdAdLƪU+d/`)393b4IR!qifdaK)(:#s"ɨ3 &$$;%EqԔ՚55(o5뫜2'm+`,7/S;8<$T*'oc(v3c˫&>eh+~.垳bRl1
_O&H!'y"$5b
1CI H:-Fh:5r T&.*o@\>yFu:)=g(K-YB--gMpPA7d87}g}=$O%/@$jnaJzru <(OC<O